Clinical significance of the highly sensitive fucosylated fraction of α-fetoprotein in patients with chronic liver disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 4, 2011, Pages 739-744

  Hanaoka, Takuya ^a   Sato, Shuichi ^a   Tobita, Hiroshi ^a   Miyake, Tatsuya ^a   Ishihara, Shunji ^a   Akagi, Shuji ^c   Amano, Yuji ^b   Kinoshita, Yoshikazu ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b SHIMANE UNIVERSITY HOSPITAL   (Japan)

^c Oda Municipal Hospital   (Japan)

Author keywords

Chronic liver disease; Fucosylated fraction; Hepatocellular carcinoma; fetoprotein

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN;

ARTICLE; CANCER INCIDENCE; CHRONIC LIVER DISEASE; CLINICAL FEATURE; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SEX RATIO;

EID: 79952833267     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06585.x     Document Type: Article

References (25)

1. Di Bisceglie AM, Rustgl VK, Hoofnagle JH etal. NIH conference. Hepatocellular carcinoma. Ann. Intern. Med. 1988; 10: 390-401.
2. Zaman SN, Melia VM, Johnson RD etal. Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients. Lancet. 1985; 15: 1357-60.
3. Miyaaki H, Nakashima O, Kurogi M etal. Lens culinaris agglutinin-reactive α-fetoprotein and protein induced by vitamin K absence are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J. Gastroenterol. 2007; 42: 962-8.
4. Durazo FA, Blatt LM, Corey WG etal. Des-γ-carboxy prothrombin, α-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2008; 23: 1541-8.
5. Kobayashi M, Kuroiwa T, Suda T etal. Fucosylated fraction of alpha-fetoprotein, L3, as a useful prognostic factor in patiens with hepatocellular carcinoma with special reference to low concentrations of serum alpha-fetoprotein. Hepatol. Res. 2007; 37: 914-22.
6. Sassa T, Kumada T, Nakano S etal. Clinical utility of simultaneous measurement of serum high-sensitivity des-gamma-carboxy prothrombin and Lens culinaris agglutinin A-reactive alpha-fetoprotein in patients with small hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 1999; 11: 1387-92.
7. Yoshida S, Kurokohchi K, Arima K etal. Clinical significance of Lens culinaris agglutinin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma. Int. J. Oncol. 2002; 20: 305-9.
8. Kawabata T, Wada HG, Watanabe M etal. "Electrokinetic Analyte Transport Assay" for alpha-fetoprotein immunoassay integrates mixing, reaction and separation on-chip. Electrophoresis. 2008; 29: 1399-406.
9. Kagebayashi C, Yamaguchi I, Akinaga A etal. Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. Anal. Biochem. 2009; 388: 306-11.
10. Toyoda H, Kumada T, Kiriyama S etal. Prognostic significance of simultaneous of three tumor markers in patients with hepatocelluar carcinoma. Clin. Gastroenterol. Hepatol. 2006; 4: 111-7.
11. Marrero JA, Feng Z, Wang Y etal. Alpha-fetoprotein, des-gamma-carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009; 137: 110-8.
12. Hayashi K, Kumada T, Nakano S etal. Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am. J. Gastroenterol. 1999; 94: 3028-33.
13. Tateishi R, Shiina S, Yoshida H etal. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers. Hepatology. 2006; 44: 1518-27.
14. Khien VV, Mao HV, Chinh TT etal. Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatoellular carcinoma. Int. Biol. Merkers. 2001; 16: 105-11.
15. Hagiwara S, Kudo M, Kawasaki T etal. Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. J. Gastroenterol. 2006; 41: 1214-9.
16. Tada T, Kumada T, Toyoda H etal. Relationship between Lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma. Liver Int. 2005; 25: 848-53.
17. Oka H, Saito A, Ito K etal. Collaborative Hepato-Oncology Study Group of Japan. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive alpha-fetoprotein. J. Gastroenterol. Hepatol. 2001; 16: 1378-83.
18. Tamura Y, Igarashi M, Suda T etal. Fucosylated fraction of alpha-fetoprotein as a predictor of prognosis in patients with hepatocellular carcinoma after curative treatment. Dig. Dis. Sci. 2010; 55: 2095-101.
19. Toyoda H, Kumada T, Kaneoka Y etal. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J. Hepatol. 2008; 49: 223-32.
20. Yamashita F, Tanaka M, Satomura S etal. Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology. 1996; 111: 996-1001.
21. Tateishi R, Yoshida H, Matsunaga Y etal. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol. Int. 2008; 2: 17-30.
22. Sterling RK, Jeffers L, Gordon F etal. Utility of lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothronbin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 2009; 7: 104-13.
23. Sterling RK, Jeffers L, Gordon F etal. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am. J. Gastroenterol. 2007; 102: 2196-205.
24. Tamura Y, Igarashi M, Kawai H etal. Clinical advantage of highly sensitive on-chip immunoassay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma. Dig. Dis. Sci. 2010; 55: 2576-83.
25. Woo HY, Jang JW, Choi JY etal. Tumor doubling time after initial response to transarterial chemoembolization in patients with hepatocellular carcinoma. Scand. J. Gastroenterol. 2010; 45: 332-9.